Humacyte, Inc. (HUMA)
| Market Cap | 242.00M +28.9% |
| Revenue (ttm) | 2.02M +289.9% |
| Net Income | -95.22M |
| EPS | -0.55 |
| Shares Out | 222.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,353,387 |
| Open | 1.025 |
| Previous Close | 1.050 |
| Day's Range | 1.020 - 1.100 |
| 52-Week Range | 0.547 - 2.930 |
| Beta | 2.31 |
| Analysts | Buy |
| Price Target | 5.00 (+358.72%) |
| Earnings Date | May 13, 2026 |
About HUMA
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would tar... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for HUMA stock is "Buy." The 12-month stock price target is $5.0, which is an increase of 358.72% from the latest price.
News
Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
- Dialysis access requires frequent cannulation, often exceeding 300 needle punctures annually - - The ATEV was observed to maintain long-term structural integrity and self-repair with smooth muscle ...
Humacyte reports Symvess under contract with Strategic Acquisition Center of VA
Humacyte (HUMA) announced that Symvess is now under contract with the with Strategic Acquisition Center of the U.S. Department of Veterans Affairs. The SAC contract makes Symvess more easily accessibl...
Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospitals – - SAC awards require intensive product and value analysis vetting by a surgical committee and s...
Humacyte price target raised to $1.50 from $1 at TD Cowen
TD Cowen analyst Joshua Jennings raised the firm’s price target on Humacyte (HUMA) to $1.50 from $1 and keeps a Buy rating on the shares. The firm updated its model…
Humacyte Q1 Earnings Call Highlights
Humacyte NASDAQ: HUMA reported first-quarter 2026 Symvess sales of $0.5 million and outlined a series of commercial, clinical and cost-reduction initiatives aimed at accelerating adoption of its bioen...
Humacyte reports Q1 EPS (9c), consensus (12c)
Reports Q1 revenue $495,000, consensus $1.46M. “We have seen expansion in the commercial uptake of Symvess. We also recognize that more rapid growth and expansion of sales is necessary and…
Humacyte Earnings Call Transcript: Q1 2026
First quarter Symvess sales grew fivefold year-over-year, driven by expanded U.S. and international efforts, new leadership, and a revamped commercial strategy. Interim phase III dialysis trial results are expected in June, with a supplemental BLA planned for late 2026.
Humacyte Earnings release: Q1 2026
Humacyte released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Humacyte Quarterly report: Q1 2026
Humacyte has published its Q1 2026 quarterly earnings report on May 13, 2026.
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer - - First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in 2025 ...
Humacyte names Todd Rasmussen chief surgical officer
Humacyte (HUMA) announced that Todd Rasmussen has joined the company as chief surgical officer. In this role, Rasmussen will focus on providing peer-to-peer scientific support, medical education, and ...
Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer
- Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership to new role at cutting-edge biotech manufacturer -
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced...
Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026
DURHAM, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comme...
Humacyte Transcript: KOL event
ATEV showed superior usability, durability, and safety over AV fistula in women with ESKD, reducing catheter dependence and related complications. Adoption is expected to expand from high-risk groups as clinical experience and supportive payment models grow.
Humacyte Proxy statement: Proxy filing
Humacyte filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026
DURHAM, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at com...
Humacyte realigns ex-U.S. rights to Symvess through Fresenius Medical pact
Humacyte (HUMA) announced that it has realigned the ex-U.S. rights to Symvess through an amendment to its distribution agreement with Fresenius Medical Care (FMS). “We are pleased to have worked…
Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®
- Ex-U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care - - Positions Humacyte to advance discussions with corporate partners regarding international and indi...
Humacyte Appoints Jim Mercadante as Chief Commercial Officer
– Industry veteran with more than 25 years of experience will lead next phase of biotech company's commercial expansion – – Seasoned medtech commercial leader brings extensive field-specific success i...
Humacyte announces Israeli Ministry of Health acceptance of MAA for Symvess
Humacyte (HUMA) announced that its Marketing Authorization Application, MAA, seeking approval of the acellular tissue engineered vessel for arterial trauma repair has been accepted by the Israel Minis...
Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair
- The Ministry of Health has set a 180-working-day review period for the MAA - - MAA process is one step in planned expansion of Symvess into multiple countries outside of the U.S - DURHAM, N.C., Apr...
Humacyte Proxy statement: Proxy filing
Humacyte filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Largest borrow rate increases among liquid names
Latest data shows the largest indicative borrow rate increases among liquid option names include: Humacyte (HUMA) 16.96% +1.30, Infosys (INFY) 14.10% +1.29, Defiance 1.75x MSTR ETF (MSTX) 27.68% +1.03...
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...